AGP Executive Report
Last update: 5 hours agoCancer Research: An international phase 3 trial involving centres in Italy found that adding irinotecan to standard chemotherapy did not improve three-year disease-free survival for patients with high-risk stage III colon cancer: rates were 65.6% versus 66.3%. Antibiotic Use: A study of nearly 593,000 COVID-19 hospital patients across 64 countries found that 75.6% received antibiotics, while suspected or confirmed bacterial infections were reported in just 7.9%. Antibiotic use was associated with higher 28-day in-hospital mortality, though the findings do not prove it caused the increase.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.